Trevogrumab ± garetosmab + semaglutide
Regeneron
Myostatin blockade, with or without activin A blockade, alongside semaglutide.
Selected study results
COURAGE · lower-dose portionLean-mass change by DXA · primary endpointDXA lean mass decreased 4.2% · 52 weeks · Phase 2
Lean-mass change by DXA · primary endpoint · 52 weeks
Study focus: Comparative weight management
Lower-dose 52-week results. Absolute arm means below retain the October 1 sponsor source; the journal comparison and confidence intervals are listed separately.
Adults aged 18–80 years with BMI ≥30 kg/m²; publication Part B, the 52-week lower-dose portion · Trevogrumab 25 or 75 mg with semaglutide 2.4 mg · Trial N=376 · Published analysis: randomized participants receiving at least one dose, efficacy as assigned. Displayed absolute arm means are from the October 1 sponsor report; the journal reports between-group differences. No formal estimand is named in the abstract.. Results & methods ↗ · Publication ↗
| Arm, each with semaglutide 2.4 mg | Week 26 | Week 52 (primary) |
|---|---|---|
| Placebo | −6.7% | −7.3% |
| Trevogrumab 25 mg | −4.7% | −5.8% |
| Trevogrumab 75 mg | −3.3% | −4.2% |
- Earlier higher-dose and triplet portionThe earlier 26-week triplet result used trevogrumab 400 mg and garetosmab 10 mg/kg with semaglutide. It is a separate portion of the same protocol and should not be combined with the lower-dose 52-week estimates. Follow-up source ↗
- November 11 journal · 52-week lower-dose Part BPart B n=376. Semaglutide plus placebo lean-mass change was −7.3% (95% CI −8.8 to −5.8). Estimated treatment differences versus semaglutide plus placebo were +1.5 percentage points (95% CI −0.3 to +3.3) with trevogrumab 25 mg and +3.1 points (95% CI +1.3 to +4.9) with 75 mg. These are between-group differences, not total active-arm changes. Follow-up source ↗
- November 11 journal · separate higher-dose Part A safetyIn the 26-week semaglutide plus trevogrumab 400 mg plus garetosmab 10 mg/kg group, serious adverse events occurred in 14/149, treatment discontinuations in 48/149 and muscle spasms in 61/149. Two deaths occurred in this group; a causal association with treatment was not identified. These are not the 25/75-mg lower-dose arms. Follow-up source ↗
The journal reports no significant fat-mass or body-weight difference in the lower-dose Part B comparisons. Less DXA lean-mass loss does not establish preserved strength or physical function. The higher-dose triplet has a separate safety assessment. The current registry total is not the size of this published analysis.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Safety context
The higher-dose triplet had unfavorable tolerability: 14/149 serious adverse events, 48/149 treatment discontinuations and 61/149 muscle spasms in the published Part A. Two deaths occurred in that group; a causal association with treatment was not identified. The paper describes trevogrumab without garetosmab as having safety similar to semaglutide plus placebo. These findings do not establish a physical-function benefit.
Mechanism at a glance
Body-composition and other targets appear alongside hormone pathways in this overview.
Explore the hormone anatomy ↗Obesity stage by formulation
Latest: The Lancet published the full COURAGE trial on November 11, 2026, including the separate 52-week lower-dose portion and 26-week higher-dose safety findings.
Next: Further evaluation is needed to determine whether the body-composition changes improve physical function or long-term health.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies1 record
COURAGE
Weight managementRegistry records actual completion on October 21, 2026 (posted November 12). The Lancet report calls the 26-week higher-dose cohort Part A and the 52-week lower-dose cohort Part B; the registry uses different part labels after a healthy-volunteer portion. Current registry enrollment is 1,005 and must not replace the publication-specific populations, including lower-dose Part B n=376. No registry results are posted.
